ATE298344T1 - Biokonjugate und verabreichung von bioaktiven substanzen - Google Patents

Biokonjugate und verabreichung von bioaktiven substanzen

Info

Publication number
ATE298344T1
ATE298344T1 AT97939382T AT97939382T ATE298344T1 AT E298344 T1 ATE298344 T1 AT E298344T1 AT 97939382 T AT97939382 T AT 97939382T AT 97939382 T AT97939382 T AT 97939382T AT E298344 T1 ATE298344 T1 AT E298344T1
Authority
AT
Austria
Prior art keywords
bioactive agent
bioconjugates
release
site
cleavage
Prior art date
Application number
AT97939382T
Other languages
English (en)
Inventor
Charles B Grissom
Frederick G West
W Allen Howard Jr
Original Assignee
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah Res Found filed Critical Univ Utah Res Found
Application granted granted Critical
Publication of ATE298344T1 publication Critical patent/ATE298344T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT97939382T 1996-08-27 1997-08-22 Biokonjugate und verabreichung von bioaktiven substanzen ATE298344T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2443096P 1996-08-27 1996-08-27
US2503696P 1996-08-27 1996-08-27
PCT/US1997/014140 WO1998008859A1 (en) 1996-08-27 1997-08-22 Bioconjugates and delivery of bioactive agents

Publications (1)

Publication Number Publication Date
ATE298344T1 true ATE298344T1 (de) 2005-07-15

Family

ID=26698439

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97939382T ATE298344T1 (de) 1996-08-27 1997-08-22 Biokonjugate und verabreichung von bioaktiven substanzen

Country Status (11)

Country Link
US (4) US6315978B1 (de)
EP (1) EP1007533B1 (de)
JP (1) JP2001501596A (de)
AT (1) ATE298344T1 (de)
AU (1) AU738431B2 (de)
CA (1) CA2264592C (de)
DE (1) DE69733618T2 (de)
ES (1) ES2244006T3 (de)
NZ (1) NZ334870A (de)
PT (1) PT1007533E (de)
WO (1) WO1998008859A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739313A (en) 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
US6806363B1 (en) 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
AU4243700A (en) * 1999-04-16 2000-11-02 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as antitumor agents
CA2387757A1 (en) * 1999-10-15 2001-04-26 Henricus P. C. Hogenkamp Cobalamin conjugates useful as imaging agents and as antitumor agents
EP1239887A1 (de) 1999-10-15 2002-09-18 Mayo Foundation For Medical Education And Research Cobalamin-konjugate geeignet zur verwendung wie bilderzeugungs- oder therapeutische mitteln
US7591995B2 (en) * 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6797521B2 (en) * 1999-10-26 2004-09-28 University Of Utah Research Foundation Fluorescent cobalamins and uses thereof
DE10012120A1 (de) 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
WO2001092283A2 (en) * 2000-05-31 2001-12-06 Mayo Foundation For Medical Education And Research Cobalamin compounds useful as cardiovascular agents and as imaging agents
AU2001272935A1 (en) * 2000-05-31 2001-12-11 Mayo Foundation For Medical Education And Research Cobalamin compounds useful as antibiotic agents and as imaging agents
WO2002055530A2 (en) * 2000-10-25 2002-07-18 Mayo Foundation Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
EP1754712A3 (de) * 2000-10-25 2009-01-14 Mayo Foundation For Medical Education And Research Transcobalamin-bindende Konjugate zur Behandlung abnormaler zellulärer Proliferation
EP1343492B1 (de) * 2000-11-22 2006-02-01 Rxkinetix, Inc. Behandlung von mukositis
WO2002076394A2 (en) * 2001-03-22 2002-10-03 The Ohio State University Research Foundation Enzyme-based anti-cancer compositions and methods
US6752986B2 (en) * 2001-05-24 2004-06-22 The Cleveland Clinic Foundation Composition and methods for affecting metallocorrinoid uptake
US20030031627A1 (en) * 2001-07-31 2003-02-13 Mallinckrodt Inc. Internal image antibodies for optical imaging and therapy
EP1435973A4 (de) * 2001-09-28 2007-05-02 Mayo Foundation Gleichzeitige verabreichung eines transportproteins mit konjugiertem cobalamin zur abgabe von mitteln
US6679827B2 (en) 2001-10-11 2004-01-20 Robert E. Sandstrom Magnetic field enhancement of tumor treatment
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20040047917A1 (en) * 2002-09-06 2004-03-11 Stephen Wilson Drug delivery and targeting with vitamin B12 conjugates
CA2516453A1 (en) * 2003-02-20 2004-09-02 The Cleveland Clinic Foundation Composition and methods for inhibiting cell survival
US7232805B2 (en) * 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
US7119065B2 (en) * 2003-10-29 2006-10-10 Nagoya Industrial Science Research Institute Metal complex-protein composite and oxidation catalyst
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US7840263B2 (en) 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7729761B2 (en) * 2004-07-14 2010-06-01 Cardiac Pacemakers, Inc. Method and apparatus for controlled gene or protein delivery
EP1789391B1 (de) 2004-07-23 2017-06-28 Endocyte, Inc. Zweiwertige linker und konjugate davon
US8202507B2 (en) * 2004-09-23 2012-06-19 The Regents Of The University Of California Assay for vitamin B12 absorption and method of making labeled vitamin B12
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
BRPI0610419A2 (pt) * 2005-05-17 2012-10-23 Cargill Inc lecitina granular, lisolecitina, processo para produzir lecitina granular, composição granular, processo para produzir uma composição de lecitina granular, produto, e, processos para produzir lisolecitina granular e para produzir uma composição de lisolecitina granular
CN103893778A (zh) * 2005-08-19 2014-07-02 恩多塞特公司 多药物配体缀合物
US7774057B2 (en) 2005-09-06 2010-08-10 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression for cardiac protection
AU2006320538B2 (en) * 2005-11-30 2013-07-04 Endo Pharmaceuticals Inc. Treatment of xerostomia with a sulfur-containing antioxidant
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
US8883723B2 (en) 2007-03-05 2014-11-11 Syracuse University Conjugate of insulin and vitamin B12 for oral delivery
EP2139523B1 (de) 2007-03-14 2014-10-22 Endocyte, Inc. Konjugate aus folat und tubulysinen zur zielgerichteten wirkstofffreisetzung
US20080233135A1 (en) * 2007-03-19 2008-09-25 Gebhard John R Cobalamin taxane bioconjugates
JP5634862B2 (ja) 2007-05-16 2014-12-03 カーテーベー トゥモーアフォルシュングス ゲゼルシャフト ミット ベシュレンクテル ハフツング 低粘度アントラサイクリン製剤
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
BRPI0812970A2 (pt) 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
US8227204B2 (en) * 2007-10-18 2012-07-24 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
US9557635B2 (en) * 2007-10-18 2017-01-31 Gearbox, Llc Ionizing-radiation-responsive compositions, methods, and systems
GB2453860B (en) 2007-10-18 2011-03-16 Searete Llc Ionizing-radiation-responsive compositions,methods and systems
US8684898B2 (en) * 2007-10-18 2014-04-01 The Invention Science Fund I Llc Ionizing-radiation-responsive compositions, methods, and systems
US20090104113A1 (en) * 2007-10-18 2009-04-23 Searete Llc Ionizing-radiation-responsive compositions, methods, and systems
US8529426B2 (en) 2007-10-18 2013-09-10 The Invention Science Fund I Llc Ionizing-radiation-responsive compositions, methods, and systems
US8164074B2 (en) * 2007-10-18 2012-04-24 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
US8168958B2 (en) * 2007-10-18 2012-05-01 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
US20090169484A1 (en) 2007-12-28 2009-07-02 Ihi Corporation Iron-salen complex
JP2009274962A (ja) * 2008-05-12 2009-11-26 Yoshihiro Ishikawa 鉄サレン錯体、磁性を有する薬剤、薬剤の誘導システム、並びに磁気検出装置
CA2731503A1 (en) * 2008-07-21 2010-01-28 Osiris Therapeutics, Inc. Taxane compounds for treating eye disease
EP2357166B1 (de) 2008-11-20 2020-01-15 IHI Corporation Automagnetische metall-salen-komplexverbindung
CN102834512A (zh) * 2010-04-06 2012-12-19 株式会社Ihi 金属salen配合物衍生物及其制造方法
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
KR20140026396A (ko) 2011-03-08 2014-03-05 어섹스 팔마큐티칼스 인코포레이티드 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
MX2015004757A (es) 2012-10-16 2015-07-17 Endocyte Inc Conjugados de suministro de farmacos que contienen aminoacidos no naturales y metodo para usarlos.
US9352049B2 (en) 2013-03-14 2016-05-31 Albany Molecular Research, Inc. Ligand-therapeutic agent conjugates, silicon-based linkers, and methods for making and using them
WO2014168950A1 (en) * 2013-04-08 2014-10-16 University Of North Carolina At Chapel Hill Photo-responsive compounds
UY35582A (es) * 2013-05-22 2014-10-31 Alnylam Pharmaceuticals Inc COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO
GR20130100654A (el) * 2013-11-22 2015-06-18 Χρηστος Γκολφινου Ταπεινος Επιφανειακως τροποποιημενα πολλαπλως αποκρινομενα σε ερεθισματα νανο/μικρο-δοχεια ως φορεις φαρμακων για στοχευμενη θεραπεια διαφορων μορφων καρκινου
GB202018713D0 (en) 2020-11-27 2021-01-13 Quadram Inst Bioscience Methods and compositions utilising vitamin b12 binding

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4758421A (en) * 1985-03-15 1988-07-19 The Board Of Trustees Of The Leland Stanford Junior University Bleomycin conjugates and method
NZ217821A (en) 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
JP3095752B2 (ja) * 1987-07-15 2000-10-10 アメリカ合衆国 Ｔａｇ‐７２及びヒト癌腫に対して結合特異性を有する第二世代モノクローナル抗体及びその使用方法
US5047227A (en) * 1988-02-08 1991-09-10 Cytogen Corporation Novel and improved antibodies for site specific attachment of compounds
WO1990012095A1 (en) * 1989-04-03 1990-10-18 Purdue Research Foundation Method for enhancing transmembrane transport of exogenous molecules
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
WO1994028015A1 (en) * 1993-05-20 1994-12-08 Biotech Australia Pty. Limited Lhrh antagonists
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
ATE225799T1 (de) * 1994-04-08 2002-10-15 Receptagen Corp Rezeptor modulierendes mitteln und entsprechendes verfahren
US5574018A (en) * 1994-07-29 1996-11-12 Amgen Inc. Conjugates of vitamin B12 and proteins

Also Published As

Publication number Publication date
US20020049154A1 (en) 2002-04-25
AU4148297A (en) 1998-03-19
US6790827B2 (en) 2004-09-14
AU738431B2 (en) 2001-09-20
DE69733618D1 (de) 2005-07-28
EP1007533B1 (de) 2005-06-22
JP2001501596A (ja) 2001-02-06
DE69733618T2 (de) 2006-05-11
US6777237B2 (en) 2004-08-17
NZ334870A (en) 2000-12-22
US6776976B2 (en) 2004-08-17
ES2244006T3 (es) 2005-12-01
US6315978B1 (en) 2001-11-13
PT1007533E (pt) 2005-09-30
CA2264592C (en) 2012-02-21
EP1007533A1 (de) 2000-06-14
EP1007533A4 (de) 2002-08-07
US20020115595A1 (en) 2002-08-22
US20020111294A1 (en) 2002-08-15
WO1998008859A1 (en) 1998-03-05
CA2264592A1 (en) 1998-03-05

Similar Documents

Publication Publication Date Title
DE69733618D1 (de) Biokonjugate und verabreichung von bioaktiven substanzen
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
ATE264114T1 (de) Zyklodexrinpolymere zum gebrauch als medikamententräger
PH12016500941A1 (en) Protection, restoration, and enhancement for erythropoietin-responsive cells, tissues and organs
BR9912053A (pt) Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios
WO1996025947A3 (en) Induction of e-selectin for targetting therapeutic agents
WO2003105757A3 (en) METHODS AND COMPOSITIONS FOR MEDIA-DEPENDENT BINDING OF A TARGET AGENT TO A TARGET
DE59611341D1 (de) Verwendung von saccharid-konjugaten
TR200103469T2 (tr) Amiloidojenik hastalığının önlenmesi ve tedavisi
ID26042A (id) Turunan-turunan asam lemak dari asam-asam empedu dan asam empedu
WO2005097219A3 (en) Ecm-based graft material
TR200003161T2 (tr) Poliol-IFN-Beta konjugatları
ATE314067T1 (de) Cannabinol-11-säurederivate als entzündungshemmer und analgetika
RU2719598C1 (ru) Применение пептида нервных нитей для предупреждения или уменьшения прогрессирования рака предстательной железы
KR100537343B1 (ko) 관절염 치료용 초음파 장치
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
MX9101448A (es) Agentes quimioterapeuticos y metodo para hacerlos
HK1025793A1 (en) Hepatitis c receptor protein cd81
GT200000035AA (es) Derivados de resorcinol, (solicitud fraccionaria no. 1 derivada de la patente pi-2000-0035)
ATE246929T1 (de) Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen
KR20210133132A (ko) 세포사멸 유도용 기체 전구체를 담지한 나노입자 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
Wang et al. Drug delivery strategies for cathepsin inhibitors in joint diseases
Chaturvedi et al. Melanotropic peptides: biomedical applications
WO2003103614A3 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF OEDEMATUS FIBROSCLEREUS PANNICULOPATHY
D Sharma Assessment of Dental Bond strength after selective Pre-treatment of dentin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1007533

Country of ref document: EP